NasdaqGS:SILK

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Silk Road Medical, Inc. operates as a medical device company in the United States. More Details


Snowflake Analysis

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has Silk Road Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SILK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: SILK's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

2.4%

SILK

-2.5%

US Medical Equipment

-0.06%

US Market


1 Year Return

64.0%

SILK

18.4%

US Medical Equipment

19.0%

US Market

Return vs Industry: SILK exceeded the US Medical Equipment industry which returned 18.4% over the past year.

Return vs Market: SILK exceeded the US Market which returned 19% over the past year.


Shareholder returns

SILKIndustryMarket
7 Day2.4%-2.5%-0.06%
30 Day-1.4%-0.7%4.4%
90 Day8.6%5.5%6.3%
1 Year64.0%64.0%19.4%18.4%21.7%19.0%
3 Yearn/a68.7%64.4%46.4%36.7%
5 Yearn/a138.5%120.2%91.0%69.9%

Long-Term Price Volatility Vs. Market

How volatile is Silk Road Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Silk Road Medical undervalued compared to its fair value and its price relative to the market?

17.26x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: SILK ($61) is trading above our estimate of fair value ($54.35)

Significantly Below Fair Value: SILK is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: SILK is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: SILK is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SILK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SILK is overvalued based on its PB Ratio (17.3x) compared to the US Medical Equipment industry average (4.5x).


Next Steps

Future Growth

How is Silk Road Medical forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

70.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SILK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: SILK is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SILK's is expected to become profitable in the next 3 years.

Revenue vs Market: SILK's revenue (28% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: SILK's revenue (28% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SILK is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Silk Road Medical performed over the past 5 years?

34.8%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: SILK is currently unprofitable.

Growing Profit Margin: SILK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if SILK's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare SILK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SILK is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.6%).


Return on Equity

High ROE: SILK has a negative Return on Equity (-32.49%), as it is currently unprofitable.


Next Steps

Financial Health

How is Silk Road Medical's financial position?


Financial Position Analysis

Short Term Liabilities: SILK's short term assets ($177.7M) exceed its short term liabilities ($15.1M).

Long Term Liabilities: SILK's short term assets ($177.7M) exceed its long term liabilities ($49.0M).


Debt to Equity History and Analysis

Debt Level: SILK's debt to equity ratio (37.7%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if SILK's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SILK has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if SILK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Silk Road Medical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SILK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SILK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SILK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SILK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SILK's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Erica Rogers (56 yo)

8.08yrs

Tenure

US$3,679,061

Compensation

Ms. Erica J. Rogers serves as the Chief Executive Officer and President of Silk Road Medical Inc since October 2012. Ms. Rogers serves as Director at Sight Sciences, Incorporated. Ms. Rogers served as Chie...


CEO Compensation Analysis

Compensation vs Market: Erica's total compensation ($USD3.68M) is about average for companies of similar size in the US market ($USD4.20M).

Compensation vs Earnings: Erica's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Erica Rogers
President8.08yrsUS$3.68m0.54%
$ 11.1m
Lucas Buchanan
CFO & COO4.33yrsUS$1.39m0.35%
$ 7.3m
Andrew Davis
Chief Commercial Officer0.33yrUS$1.22m0.042%
$ 867.5k
Mhairi Jones
Vice President of Finance & Accountingno datano datano data
Matthew McCarthy
Vice President of Marketing1yrno datano data
Alison Highlander
Vice President of Human Resourcesno datano datano data
Sumaira MacDonald
Executive Medical Director6.83yrsno datano data
Richard Reudy
Executive Vice President of Clinical & Regulatory Affairs and Quality Assuranceno datano data0.047%
$ 967.5k
William Whealon
Executive Vice President of Research & Development0.17yrno datano data
Lynn Lewis
Investors Relations Officerno datano datano data

2.7yrs

Average Tenure

52yo

Average Age

Experienced Management: SILK's management team is considered experienced (2.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Erica Rogers
President8.08yrsUS$3.68m0.54%
$ 11.1m
Jack Lasersohn
Independent Director13.58yrsUS$136.07k0.028%
$ 582.5k
Elizabeth Weatherman
Independent Director7.58yrsUS$129.61k0.81%
$ 16.8m
Donald Zurbay
Independent Director2.67yrsUS$131.58k0%
$ 0
Rick Anderson
Director0.083yrno datano data
Tony Chou
Independent Director13.67yrsUS$120.40k0.28%
$ 5.9m
Ruoxi Chen
Independent Director4.25yrsUS$134.40k0%
$ 0

7.6yrs

Average Tenure

59yo

Average Age

Experienced Board: SILK's board of directors are considered experienced (7.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10%.


Top Shareholders

Company Information

Silk Road Medical, Inc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Silk Road Medical, Inc
  • Ticker: SILK
  • Exchange: NasdaqGS
  • Founded: 2007
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$2.071b
  • Shares outstanding: 33.96m
  • Website: https://silkroadmed.com

Number of Employees


Location

  • Silk Road Medical, Inc
  • 1213 Innsbruck Drive
  • Sunnyvale
  • California
  • 94089
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SILKNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDApr 2019
2OWBST (Boerse-Stuttgart)YesCommon StockDEEURApr 2019
2OWDB (Deutsche Boerse AG)YesCommon StockDEEURApr 2019

Biography

Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularizati...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/24 00:04
End of Day Share Price2020/11/23 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.